HANDOK Inc. (002390.KS)
KRW 12270.0
(-2.54%)
KRW 12270.0
(-2.54%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 151.36 Billion KRW | -12.86% |
| 2022 | 173.71 Billion KRW | 3.68% |
| 2021 | 167.54 Billion KRW | -0.5% |
| 2020 | 168.39 Billion KRW | 1.44% |
| 2019 | 165.99 Billion KRW | 5.21% |
| 2018 | 157.77 Billion KRW | 18.75% |
| 2017 | 132.86 Billion KRW | 4.2% |
| 2016 | 127.51 Billion KRW | 6.05% |
| 2015 | 120.23 Billion KRW | 5.11% |
| 2014 | 114.39 Billion KRW | 15.41% |
| 2013 | 99.12 Billion KRW | -0.37% |
| 2012 | 99.48 Billion KRW | -19.78% |
| 2011 | 124.02 Billion KRW | -1.01% |
| 2010 | 125.28 Billion KRW | 7.75% |
| 2009 | 116.27 Billion KRW | -4.43% |
| 2008 | 121.66 Billion KRW | -5.27% |
| 2007 | 128.42 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 128.36 Billion KRW | -6.98% |
| 2024 Q1 | 39.61 Billion KRW | 20.57% |
| 2024 Q2 | 39.04 Billion KRW | -1.43% |
| 2023 Q2 | 46.55 Billion KRW | 12.52% |
| 2023 Q1 | 41.37 Billion KRW | -4.86% |
| 2023 FY | 151.36 Billion KRW | -12.86% |
| 2023 Q3 | 41.74 Billion KRW | -10.32% |
| 2023 Q4 | 32.85 Billion KRW | -21.3% |
| 2022 Q3 | 45.92 Billion KRW | 8.24% |
| 2022 Q2 | 42.42 Billion KRW | 1.3% |
| 2022 FY | 173.71 Billion KRW | 3.68% |
| 2022 Q4 | 43.48 Billion KRW | -5.31% |
| 2022 Q1 | 41.88 Billion KRW | -1.07% |
| 2021 Q3 | 43.19 Billion KRW | 3.33% |
| 2021 Q1 | 40.21 Billion KRW | -7.92% |
| 2021 Q2 | 41.8 Billion KRW | 3.95% |
| 2021 Q4 | 42.33 Billion KRW | -1.99% |
| 2021 FY | 167.54 Billion KRW | -0.5% |
| 2020 FY | 168.39 Billion KRW | 1.44% |
| 2020 Q1 | 39.14 Billion KRW | -11.94% |
| 2020 Q2 | 41.85 Billion KRW | 6.93% |
| 2020 Q4 | 43.67 Billion KRW | -0.1% |
| 2020 Q3 | 43.72 Billion KRW | 4.46% |
| 2019 Q1 | 40.04 Billion KRW | -3.06% |
| 2019 Q3 | 40.84 Billion KRW | 0.45% |
| 2019 Q4 | 44.44 Billion KRW | 8.81% |
| 2019 FY | 165.99 Billion KRW | 5.21% |
| 2019 Q2 | 40.66 Billion KRW | 1.55% |
| 2018 Q2 | 39.35 Billion KRW | 8.46% |
| 2018 Q4 | 41.3 Billion KRW | 1.18% |
| 2018 FY | 157.77 Billion KRW | 18.75% |
| 2018 Q1 | 36.28 Billion KRW | 22.23% |
| 2018 Q3 | 40.82 Billion KRW | 3.74% |
| 2017 Q4 | 29.68 Billion KRW | -16.89% |
| 2017 FY | 132.86 Billion KRW | 4.2% |
| 2017 Q3 | 35.71 Billion KRW | 4.69% |
| 2017 Q2 | 34.11 Billion KRW | 2.35% |
| 2017 Q1 | 33.33 Billion KRW | -0.57% |
| 2016 Q4 | 33.52 Billion KRW | 4.59% |
| 2016 Q1 | 29.62 Billion KRW | -19.8% |
| 2016 FY | 127.51 Billion KRW | 6.05% |
| 2016 Q2 | 32.29 Billion KRW | 9.02% |
| 2016 Q3 | 32.05 Billion KRW | -0.75% |
| 2015 Q3 | 30.16 Billion KRW | 10.58% |
| 2015 Q1 | 25.84 Billion KRW | 0.0% |
| 2015 FY | 120.23 Billion KRW | 5.11% |
| 2015 Q2 | 27.28 Billion KRW | 5.54% |
| 2015 Q4 | 36.93 Billion KRW | 22.45% |
| 2014 FY | 114.39 Billion KRW | 15.41% |
| 2014 Q3 | 29.34 Billion KRW | -4.11% |
| 2014 Q2 | 30.6 Billion KRW | 23.9% |
| 2014 Q4 | - KRW | -100.0% |
| 2014 Q1 | 24.7 Billion KRW | -2.64% |
| 2013 Q1 | 24.16 Billion KRW | 3.95% |
| 2013 FY | 99.12 Billion KRW | -0.37% |
| 2013 Q2 | 24.51 Billion KRW | 1.46% |
| 2013 Q3 | 25.06 Billion KRW | 2.22% |
| 2013 Q4 | 25.36 Billion KRW | 1.22% |
| 2012 Q4 | 23.25 Billion KRW | -8.07% |
| 2012 Q1 | 25.77 Billion KRW | 0.0% |
| 2012 Q2 | 25.17 Billion KRW | -2.33% |
| 2012 Q3 | 25.29 Billion KRW | 0.46% |
| 2012 FY | 99.48 Billion KRW | -19.78% |
| 2011 FY | 124.02 Billion KRW | -1.01% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 32.46 Billion KRW | 2.26% |
| 2011 Q2 | 31.75 Billion KRW | 4.2% |
| 2011 Q1 | 30.47 Billion KRW | 3.58% |
| 2010 Q1 | 29.82 Billion KRW | -7.13% |
| 2010 FY | 125.28 Billion KRW | 7.75% |
| 2010 Q2 | 32.4 Billion KRW | 8.66% |
| 2010 Q3 | 33.64 Billion KRW | 3.83% |
| 2010 Q4 | 29.41 Billion KRW | -12.56% |
| 2009 Q1 | 26.96 Billion KRW | -6.35% |
| 2009 Q3 | 29.24 Billion KRW | 4.64% |
| 2009 Q2 | 27.94 Billion KRW | 3.64% |
| 2009 Q4 | 32.1 Billion KRW | 9.79% |
| 2009 FY | 116.27 Billion KRW | -4.43% |
| 2008 Q2 | 32.76 Billion KRW | 6.19% |
| 2008 Q3 | 29.24 Billion KRW | -10.76% |
| 2008 Q4 | 28.79 Billion KRW | -1.53% |
| 2008 FY | 121.66 Billion KRW | -5.27% |
| 2008 Q1 | 30.85 Billion KRW | -10.21% |
| 2007 Q4 | 34.36 Billion KRW | 15.49% |
| 2007 Q3 | 29.75 Billion KRW | -14.3% |
| 2007 Q2 | 34.72 Billion KRW | 17.39% |
| 2007 Q1 | 29.57 Billion KRW | 0.0% |
| 2007 FY | 128.42 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -225.484% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 58.428% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 23.893% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -125.165% |
| Yuhan Corporation | 564.5 Billion KRW | 73.186% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 53.023% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -537.411% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 81.891% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -101.716% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 23.922% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -272.369% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -60.15% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -7.462% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -225.484% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -336.016% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -97.045% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 1356.611% |
| JW Holdings Corporation | 446.15 Billion KRW | 66.073% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 27.066% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 76.903% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 54.906% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -92.53% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -101.183% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -109.615% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 17.653% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -225.484% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 48.71% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 77.791% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 54.906% |
| Yuhan Corporation | 564.5 Billion KRW | 73.186% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 25.0% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -113.375% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -52.854% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 54.906% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -3.753% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 12.751% |
| CKD Bio Corp. | 5.01 Billion KRW | -2921.106% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 40.461% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 17.791% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -54.258% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -92.53% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 59.255% |
| Boryung Corporation | 333.26 Billion KRW | 54.581% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -202.458% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 23.922% |
| JW Lifescience Corporation | 51.32 Billion KRW | -194.918% |